<DOC>
	<DOCNO>NCT01096576</DOCNO>
	<brief_summary>This randomize , double-blind , multiple-dose , placebo-controlled study evaluate safety , tolerability efficacy balapiravir adult male patient confirm dengue virus infection whose symptom begin within 48 hour precede first administration balapiravir . Patients randomize receive either balapiravir placebo , orally twice daily 5 day . Anticipated time treatment in-patient 7 day , out-patient follow-up week 12 . Target sample size &lt; 200</brief_summary>
	<brief_title>A Study Balapiravir Patients With Dengue Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<criteria>male patient , 1865 year age dengue virus infection ( confirm NS1 strip test ) symptom onset &lt; /=48 hour first study drug administration patient partner childbearing potential must use 2 form contraception 3 month receive last dose study drug BMI 18 35 positive test screen HIV use point care test , know HIV infection history disease know cause significant alteration immunologic function autoimmune disease patient take steroid immunosuppressive therapy positive test drug abuse alcohol use point care test clinically significant abnormal laboratory test result deem unassociated dengue infection , alternatively , diagnostic dengue shock syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>